# CLARITY Gastric 01 (NCT06346392)

> AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06346392
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Gastric Cancer; Gastroesophageal Junction Cancer
- Interventions: AZD0901; AZD0901; Ramucirumab+ paclitaxel; Paclitaxel; Docetaxel; Irinotecan; TAS-102; Apatinib
- Enrollment: 594
- Primary outcome: Progression Free Survival (PFS) in all randomized participants
- Primary outcome: Overall Survival (OS) for 3L+ participants

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 43
- YouTube: 3
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=clarity-gastric-01-nct06346392

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06346392", "email": "<work email>"}; the inbox owner confirms by the emailed link.